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Relationship between chronic inflammation and depression. 
Search for biomarkers and possible drug targets 
0. ABSTRACT 
It has been predicted that depression will become the second-leading cause of disability 
worldwide after human immunodeficiency virus (HIV) in 20301. Numerous recent data 
suggest an important role of inflammation in patients with depressive disorder. In fact, 
there has been found an increase of inflammatory markers in some depressed 
patients,2,3,4,5 and the administration of pro-inflammatory cytokines or their inducers has 
been shown to cause symptoms of depression.2 Besides this, it has been discovered that 
patients with chronic inflammatory diseases (rheumatoid arthritis, psoriasis, 
inflammatory bowel disease ...) show a higher prevalence of depression.6 
Therefore, we hypothesize that manifestations of depression are related to chronic 
inflammation, at least in some patients with major depressive disorder. Thereby, an anti-
inflammatory treatment may improve symptoms of depression. The general objective of 
this study is to analyse the relationship between inflammation and major depressive 
disorder (MDD) and search for potential diagnostic biomarkers and therapeutic targets.  
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1. BACKGROUND 
1.1 INTRODUCTION: 
Recent studies show that it is possible to understand the development of depression in 
some patients by dysregulated and prolonged immune activation.3,4 The behavioural 
changes may be caused by an inflammatory response that leads to a mirrored immune 
response within CNS (Neuroinflammation).7   
Activation of the immune system is the body natural reaction to infection or tissue 
damage.4 Actually, depression shares many characteristics with Sickness behaviour*: 
anhedonia, fatigue, psychomotor slowing, decreased appetite, sleep alterations…5,8 
Indeed, up to 50% of patients with chronic systemic conditions (e.g., cardiovascular 
disease, autoimmune disease, and cancer) show a clinic depression.9  
However, since nowadays psychological and physical stressors have been related to 
depression, recent studies evidence that acute and chronic stress may activate the innate 
immune system.10 
1.2 IMMUNE SYSTEM ACTIVATION BY STRESS: 
 
Stressors can activate the immune system by the production of DAMPs* (Damage-
associated molecular pattern) as ATP* and Reactive Oxygen and Nitrogen Species 
(RO&NS). These molecules are able to stimulate the Toll-Like Receptors* (TLR) leading 
the production of pro-inflammatory cytokines.  
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The most important pro-inflammatory cytokines, released by the innate immunity, with 
the ability to alter behaviour are TNF-α, IL-1β, IL-6.7,11 
Additionally, DAMPs induce the formation of a large multiprotein aggregate containing 
Nod-Like Receptors (NLR) and mature caspase-1 (Inflammasome*). The most studied 
Inflammasome is the NLRP3 which cleaves pro-IL-1β and pro-IL18 into mature IL-1β 
and IL-18, allowing their release from the cell.2,12,11   
Released IL-1β is thought to induce TNFα release because the increase in IL-1β precedes 
the increase in TNFα.12 IL-1β and TNFα induce the inflammatory response and  activate 
the adaptive immune system in the periphery11. Furthermore, TNFα induces the release 
of a variety of pro-inflammatory cytokines such as IL-6, IL-8 and IL-1β by stimulated 
macrophages.1,2,7  
Different models for Inflammasome activation by DAMPs have been proposed.11 One 
way is dependent on the stimulation of the purinergic type 2X7 receptors (P2X7*) by 
ATP*.13,9 This receptors have been found in microglial and blood cells. 
The mechanisms by which stress produces ATP is not completely understood. It is 
thought that stress leads to an increase of glutamate at the hippocampus, which in turn 
stimulates the release of ATP from astrocytes by a  Ca2+ -dependent mechanism . Other 
sources of ATP acting on microglial P2X7R are damaged or dying cells, which also can 
be induced by stress.12  
In addition, all DAMPs and PAMPs, including ATP and particulate/crystalline activators, 
induce the generation of reactive oxygen species (ROS). A ROS-dependent pathways also 
triggers NLRP3 Inflammasome complex formation.11 
The Inflammasome is one of the most important possible drug target for depression. 
Several clinical studies use as objectives the upstream signalling, such as P2X7R 
antagonist, antioxidants, and Redox cell control by glutathione-increasing therapy. 
Glutathione* is a crucial component of cellular antioxidant defences and plays an 
important role in detoxification of ROS and RNS and their toxic metabolites such as lipid 
peroxides.14  Other studies try to target the downstream signalling, including caspase-1 
inhibitors, anti-IL-1β therapy, TNF-α inhibitors and recombinant IL-1Ra15 
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For instance, it is found in rodents that the release of IL-1β is blocked by pre-treatment 
with P2X7 antagonist12 and by The Inflammasome inhibitor VX-765. As a result, 
decreased levels of interleukin-1β significantly moderated the depressive-like behaviours 
induced by chronic mild stress in these animals.13  
1.3 HOW DOES THE IMMUNE SYSTEM REACH THE BRAIN? 
As presented before, the behaviour changes may be developed by chronic 
Neuroinflammation. Even the activation of the immune system starts in the periphery, 
inflammatory signals may access the brain by humoral, neural and/or cellular pathways. 
Humoral pathway: Pro-inflammatory cytokines access the brain through structures in 
which there is no blood-brain-barrier (BBB).3,5 However, it can also bind to saturable 
transport molecules on the BBB 2 
Neural pathway:  Pro-inflammatory cytokines stimulate primary afferent nerve fibers in 
the vague nerve which transfer information to brain areas. 3, 5, 16  In a normal situation 
vague nerve suppresses innate immunity and pro-inflammatory cytokine production. 
However, the pronounced sympathovagal imbalance counteracts this mechanism, and 
consequently induces the maintenance of a chronic inflammation. 
Cellular pathway: Pro-inflammatory cytokines, notably TNF-α, are able to stimulate 
microglia to produce monocyte chemoattractant protein-1 (MCP-1) and astrocytes in 
order to produce chemokines such as CCL2 and CXCL1. These induce the recruitment 
of monocytes into the brain (parenchyma and vasculature).5 
1.4 POSSIBLE MECHANISMS BY WHICH CYTOKINES AFFECT BEHAVIOUR: 
Reduction of synaptic availability for monoamines: IL-1β and TNFα have been shown to 
increase the expression and function of the reuptake pumps of serotonin.2 In addition IFN-
α decreases the expression of serotonin receptor 1A.3  
Excitotoxicity: Tryptophan is an essential amino acid used in the brain for the synthesis 
of serotonin.3  Usually, it is catabolized by the tryptophan dioxygenase enzyme (TDO) in 
the liver, but tryptophan oxidation can also occur extrahepatic by the Indoleamine 2,3 
dioxygenase enzyme (IDO).3  IDO-induced degradation  normally is negligible but is 
highly inducible by pro-inflammatory cytokines. 3,5,10,17  
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Both enzymes degrade tryptophan along the kynurenine pathway. Kynurenine can be 
metabolized into two catabolic branches, leading to Quinolinic acid (QA) or Kynurenic 
acid (KA).3 QA, is an NMDA receptor agonist, which stimulate glutamate release and 
block glutamate reuptake by astrocytes.2 In contrast, KA is an NMDA receptor 
antagonist, and could be neuroprotective. 3 
 
In addition, 3-Hydroxykynureine (3-HK) another metabolite in the Kynurenine 
degradation generates free radical species that cause oxidative stress and lipid 
peroxidation.3,10 
Pro-inflammatory cytokines can also stimulate astrocytes and microglia to release 
reactive oxygen and nitrogen species that, in combination with 3-HK, can amplify 
oxidative stress. As a consequence, it can contribute to the loss of glial and neuronal cells 
in multiple mood-relevant brain regions.5,10 
Through the generation of reactive oxygen and nitrogen species (RO&NS), inflammatory 
cytokines have also been found to decrease the availability of tetrahydrobiopterin (BH4), 
a key enzyme co-factor in the synthesis of Dopamine2 which is also required for NO 
synthesis (a metabolite of RO&NS generation)5  
Moreover, the excessive release of glutamate by astrocytes can access extra synaptic 
NMDA receptors, which mediate excitotoxicity and decrease the production of trophic 
factors including brain-derived neurotrophic factor (BDNF). 5 
 The decrease of BDNF induced by glutamate and IL-6, alters the neural connectivity, 
produces alterations in the emotional responses and leads to impaired neuroplasticity and 
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decreased neurogenesis (particularly in the hippocampus), which have been associated 
with the origin of cognitive impairment and mood disorders10, 18. 
 
Effects on neuroendocrine function: A rich literature has demonstrated that acute 
administration of pro-inflammatory cytokines and cytokine inducers can activate the 
hypothalamic-pituitary-adrenal axis (HPA-axis).3, 5, 13 Chronic cytokine exposure may 
influence HPA axis through inhibitory effects on the cortisol receptor.5 Cytokines can 
also decrease GR alpha (active form of the receptor) and increase GR beta (inert GR 
isoform) which reduces the sensitivity of GRs to cortisol.5,10 Given the role of endogenous 
glucocorticoids in inhibiting inflammatory responses, cytokine-induced glucocorticoid 
resistance can exacerbate the uncontrolled inflammation.5 
1.5 ROLE OF PRO-INFLAMMATORY CYTOKINES: 
IL-1β exposure was widely reported to cause depressive behaviours and suppression of 
locomotor activity and social exploration.13,12 However, in a cumulative meta-analysis, it 
wasn’t neither confirmed nor refuted the association between IL-1β and MDD.19 The lack 
of association could be due to the low concentrations of IL-1β in the blood, which makes 
more difficult to determine the amount using conventional immunological assays, 20,19  
The same meta-analysis, confirmed higher levels of IL-6 and CRP* in the blood of 
patients with major depression compared to non-depressed controls at 5 years follow-
up.19 Nevertheless, no cross-sectional association was found between IL-6 and CRP with 
depressive symptoms at baseline.21  
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In this meta-analysis, the association between TNF-α and MDD was less convincing. 
Nonetheless, during TNFα therapy depressive symptoms can occur as a secondary effect, 
which suggests the existence of potential confounders modulating the association 
between TNFα and MDD.19 Furthermore, in animal studies, TNFα administration has 
found to cause depressive-like symptoms.1 
Anti-TNFα drugs are very effective in the treatment of chronic inflammatory and 
autoimmune disorders such as Rheumatoid arthritis, inflammatory bowel disease or 
Psoriasis. Recent clinical trials* have shown that anti-TNFα are effective in decreasing 
depressive symptoms associated with these disorders. A systematic review has already 
revealed that anti-TNFα drugs have an antidepressant effect and can improve the 
antidepressant response of other drugs.1, 22 
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2. HYPOTHESIS: 
Manifestations of depression are related to chronic inflammation, at least for some 
patients with Major Depressive Disorder (MDD). Thereby, an anti-inflammatory 
treatment may improve symptoms of depression in those patients. 
3. MAIN OBJECTIVE 
To analyse the relationship between inflammation and Major Depressive Disorder 
(MDD). 
4. SECONDARY OBJECTIVES: 
1. To analyse the levels of inflammatory biomarkers in patients with an episode of 
MDD and to compare them against a healthy control group. 
1.1.To assess if different grades of severity of depressive disorders are associated 
with different inflammatory profiles. 
2. To identify possible pharmacological targets which may help to ameliorate the 
symptoms of depression. 
3. To analyse the effect of anti-TNFα treatment on the severity of the depressive 
disorders and immunological profile. 
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5. OBJECTIVE 1:  TO COMPARE THE LEVELS OF INFLAMMATORY BIOMARKERS BETWEEN 
PATIENTS WITH AN EPISODE OF MDD AND HEALTHY CONTROL. 
5.1 DESIGN OF THE STUDY: 
Observational cross-sectional, case control study. 
5.2 METHODS 
The study will compare serum cytokine levels between patients with major depressive 
disorder and healthy individuals. Additionally, possible patterns of cytokine expression 
and severity of depression will be searched. 
5.3 STUDY POPULATION: 
Since the variables studied have no history of normality assumptions, based upon 
previous studies, we will select 50 patients in each group for the study. This is the 
minimum number necessary to perform a multivariate analysis with 5 independent 
variables. Moreover, in this way it will be possible to apply the central limit theorem, 
which states that above 30 sample size is enough for having good reliability in the analysis 
of the variables in relation to normality. 
The depressed group will include up to 50 patients with a new diagnosis of a Major 
Depressive Disorder episode attending at the Psychiatric Department of Hospital 
Germans Trias i Pujol. 
The diagnosis of depression will be established by using the Structured Clinical Interview 
for DSM-5 (SCID-5). It is an interview guide for making DSM-5 diagnoses by a clinician 
or trained mental health professional that is familiar with the DSM-5 classification and 
diagnostic criteria. 
The control group will consist of healthy volunteers without depression (hospital and/or 
university employees).  
Exclusion criteria (for both cohorts): 
 Pregnancy. 
 Individuals under antidepressant or antipsychotic treatment. 
 Individuals with autoimmune or infectious diseases. 
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 Individuals under immunosuppressive drugs or immune system modifiers (e.g. 
INFα or INFβ treatment). 
 Individuals with chronic systemic diseases. 
 Individuals with diabetes, obesity or metabolic syndrome. 
 Individuals with Alzheimer disease or with other cognitive problems. 
 Individuals with chronic pain or fatigue. 
 Individuals younger than 25 years or older than 60 years. 
All participants should have signed the informed consent before entering at the study.  
5.4 VARIABLES 
Possible confounding variables collected in the interview: 
 Age 
 Gender 
 Body Mass Index (BMI) 
 Socioeconomic status 
 Race 
Psychopathological variables: 
-Interview SCDI-V (Structures Clinical Interview for DSM-V) applied to the diagnosis 
of major depressive disorder. 
- Montgomery-Asberg Depression Rating Scale (MDRS) to measure depressive clinical 
severity. 23 
Biochemical variables analysed. Inflammatory biomarkers. 
 IL-1β 
 TNF-α  
 IL-6 
 CRP 
5.5 DATA COLLECTION: 
At baseline, within a period not exceeding one week from the diagnosis of depression, 
the MDRS to assess the severity of depression will be applied to the selected individuals 
and a specific interview will be designed to cover all the possible confounding variables.  
In addition, as the level of cytokines is highly variable, blood samples will be drawn three 
times every other day during one week for analysing the inflammatory biomarkers. The 
average of these results will be used as the statistical value to compensate the variability 
of cytokine levels. 
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Briefly, peripheral blood will be collected from patients and healthy volunteers at the 
same time period (8-10 a.m. in fasting conditions). Peripheral blood will be kept 2 h at 4 
ºC and centrifuged 10 min at 1800 rpm to obtain cell-free serum.  At least 5 aliquots of 
serum of each time point will be collected and kept frozen at -80ºC until use. 
Serum concentrations of IL-1β, IL-6 and TNF-α will be determined using a human 
cytokine ELISA test.24. The Enzyme Linked Immunosorbent Assay (ELISA) is a 
powerful method for detecting and quantifying a specific protein in a complex mixture. 
The method enables analysis of protein samples immobilized in microplate wells using 
specific antibodies.25 
CRP will be analysed by turbidimetry, a method which involves measurement of the 
intensity of light transmitted through a medium.26 When PCR reacts with an specific 
antibody, in the presence of polyethylene glycol, precipitating immune complexes are 
formed which cause turbidity. This is detected by the turbidimetry and is related to the 
concentration of PCR. 
5.6 STATISTICAL ANALYSIS OF THE RESULTS 
After obtaining the average levels for each patient, the main values of each group will be 
compared. If the quantitative variables follow a normal distribution the T-student test will 
be applied, if not, the parametric test Mann Whitman will be used. 
Eventually, a bivariate analysis of data obtained according to the confounding variables 
will be done.  
Additionally, once the biomarkers results will be obtained, a correlational study between 
severity score on the Montgomery test and the inflammatory biomarkers levels will be 
sought applying the ANOVA statistical multiple regression model. 
5.7 CHRONOLOGY: 
Month 1-3: Will serve to ask for authorization of the Ethics Committee of the hospital, 
to set up the protocols and to prepare the questionnaires. 
Month 3-12: Recruitment of the study individuals. Once the subjects have been selected, 
the blood drawn of the both groups will start in less than one week to avoid leaving 
patients too long without starting treatment.  
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Days 
Recruitment 
period 
(maximum 
1 week) 
0 1 2 3 4 5 6 
Diagnosis of 
Depression X        
Check 
inclusion 
criteria 
X        
Give 
information 
to the patient 
X        
Deliver 
informed 
consent 
X        
Signed 
informed 
consent 
 X       
MDRS 
questionnaire  X       
Blood drawn   X  X  X  
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6. OBJECTIVE 2:  TO IDENTIFY POSSIBLE PHARMACOLOGICAL TARGETS WHICH MAY 
HELP TO AMELIORATE THE SYMPTOMS OF DEPRESSION. 
6.1 DESIGN OF THE STUDY: 
A pilot experimental design with paired samples will be done. In this, the samples from 
each individual will be analysed in five different conditions.  
6.2 METHODS 
The 15 depressive patients who have the highest rate of inflammatory markers in the first 
study will be selected to analyse the effect of different drugs that block Inflammasome 
on dendritic cells (DC). 
 Five DC cultures from each patient will be analysed. DC will be generated from 
peripheral blood monocytes cultered for 5 days in the presence of GMCSF + IL-4 adding 
LPS stimulus (100 μg/mL) on day 4. On day 5 all will be washed and the indicated 
stimulus will be added for 24h: 
 DC + placebo (PBC) 
 DC + ATP. 
 DC + ATP + anti P2X7R ATP. 
 DC + ATP + anti-pro-IL-1β. 
 DC + ATP + caspase-1 inhibitor. 
After the incubation period, the effectiveness of the various drugs against Inflammasome 
will be analysed by comparing the amount of IL-1β secreted in the supernatant. 
6.3 STUDY POPULATION: 
Although there is not enough information from prior studies to calculate with precision 
the sample size, from similar studies of the literature it is estimated that a sample size of 
15 patients will be enough. 
6.4 VARIABLES 
The IL-1β will be the only variable analysed. 
6.5 DATA COLLECTION: 
Levels of IL-1β from culture supernatant of each sample will be evaluated using a human 
cytokine ELISA test.24.  
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6.6 STATISTICAL ANALYSIS  
The results will be compared using an analysis of variance for repeated measures. 
6.7 CHRONOLOGY  
For the study three months for the preparation of the protocols and twelve months for the 
analysis of the cultures will be needed.  
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7. OBJECTIVE 3:  TO ANALYSE THE EFFECT OF ANTI-TNF TREATMENT ON THE 
SEVERITY OF THE DEPRESSIVE DISORDERS AND IMMUNE PROFILE. 
7.1 DESIGN OF THE STUDY: 
A descriptive, prospective and longitudinal pilot study will be executed. 
7.2 METHODS 
The relationship between markers of inflammation and severity of depression will be 
analysed in patients with co-diagnosis of rheumatoid arthritis or psoriasis and resilient 
depression before starting the anti-TNF-α treatment and at 4, 12 and 24 weeks.   
7.3 STUDY POPULATION: 
There is not enough information from prior studies to calculate with precision the sample 
size. Nevertheless, it is estimated that follow up of 15-20 patients is sufficient for this 
exploratory study. 
 
Inclusion criteria: 
Diagnosis of Rheumatoid arthritis or Psoriasis  (10 individuals of each one)  attending at 
the Dermatological Department of Hospital Germans Trias i Pujol who have to start 
taking anti-TNF therapy27  and who also have diagnosis of depression with resistance to 
antidepressant drugs. 
 
All participants should have signed the informed consent before they entered the study.  
Exclusion criteria: 
 Pregnancy. 
 Individuals under antidepressants or antipsychotic treatment. 
 Individuals with another autoimmune, infectious diseases or systemic disease. 
 Individuals under immunosuppressive drugs or immune system modifiers (e.g. 
INFα). 
 Individuals with diabetes, obesity or metabolic syndrome. 
 Individuals with Alzheimer disease or with other cognitive problems. 
 Individuals with chronic pain or fatigue. 
 Individuals younger than 25 years or older than 60 years. 
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7.4 VARIABLES 
Psychopathological variables: 
-Interview SCDI-V (Structures Clinical Interview for DSM-V) applied to the diagnosis 
of major depressive disorder. 
- Montgomery-Asberg Depression Rating Scale (MDRS) to measure depressive clinical 
severity. 23 
Biochemical variables analysed. Inflammatory biomarkers. 
 IL-1β 
 TNF-α  
 IL-6 
 CRP 
Clinical parameters for patients suffering from Rheumatoid Arthritis 
 Rheumatoid Arthritis Quality of Life (RAQoL)28 to assess the quality of life of 
patients. 
 Disease Activity Score 28 (DAS28) to measure rheumatoid arthritis (RA) disease 
activity, to determine whether the signs and symptoms have reduced or stopped, 
and if treatment needs to be adjusted.29 
Clinical parameters for patients suffering from Psoriasis: 
 The Psoriasis Disability Index (PDI) as a tool for assessment of quality of life in 
psoriasis.30 
7.5 DATA COLLECTION: 
The patients will be assessed for psychosocial, immunological biomarkers and clinical 
parameters at baseline and 4, 12, 24 weeks after starting anti-TNF therapy.  For this 
purpose, the MDRS, RAQoL and DAS28 or PDI questionnaires will be performed. The 
analyse of cytokines and the used methods will be the same like in the previous study. 
7.6 STATISTICAL ANALYSIS OF THE RESULTS 
At the end of the study the results of the severity score, clinical parameters and the level 
of cytokines of each individual will be compared by an analysis of the variability in 
repeated measures. 
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7.7 CHRONOLOGY OF THE STUDY 
The study inclusion period will last 12 months. Once subjects will be selected the 
interview and blood test will be done before starting the therapy, at week 4, 12 and 24. 
Therefore, the follow-up period of all patients, including the last included, will be until 
15th month.  
WEEKS 
Recruitment 
period 
(maximum 
1 week) 
0 4 12 24 
Check 
inclusion 
criteria 
X     
Give 
information 
to the patient 
X     
Deliver 
informed 
consent 
X     
Signed 
informed 
consent 
 X    
Clinical Test  X X X X 
MDRS 
questionnaire  X X X X 
Blood drawn 
  X X X X 
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8. STUDY DURATION 
The complete study will last three years (36 months). The chronology of the study is as 
follows: 
 
9. DISSEMINATION OF RESULTS. 
The results of this study will be presented in national and international congresses of Immunology 
and Psychiatry and a review paper and at least one original peer-reviewed will be done.  
Furthermore, presentations to patient associations and seminars at IGTP will be organized. 
10. STUDY LIMITATIONS 
Objective 1: 
It is possible to find a self-selection bias because the characteristics of the group of 
patients may not correlate with the control group especially in the socioeconomic status. 
For this reason, a multivariate data analysis with possible confounders will be done. 
Another important limitation of this study is the variability of cytokines in blood and the 
variety of factors that can influence it. For this reason, in the study we will use the average 
of several samples taken at the same time of the days, in order to reduce the variability. 
Given that patients cannot stay long untreated for ethical reasons, all samples should be 
taken the first week after recruitment. In addition, the blood level of various cytokines 
might be very low, which would make more difficult find significant variation in the 
sample. 
Another measure to prevent the variation of cytokines by other factors, is the exclusion 
of the study people with mental illness or other systemic diseases. However, this would 
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make more difficult the recruitment because depression is highly associated with other 
diseases. 
Another problem is to assess the severity of depressive symptoms because it is a 
subjective parameter. For this reason, we will use the MDRA questionnaire, which 
according to various systematics reviews, is the most reliable. 
Objective 3 
Recruitment patients that are going to start anti-TNFα with co-diagnosis of depression 
should be enough based on the current amount of patients attended at the HGTP. 
However, it can be difficult to reach 20 subjects for the study.  In case, it will not be 
enough the recruitment period will be extended for six months more. 
11. EXPECTED RESULTS 
It is expected that patients with depression have elevated inflammatory markers compared 
to non-depressed subjects. As a result, an improvement in the severity of depression in 
subjects taking TNF-α is expected. 
Referred to in vitro analysis of drugs, it is expected to find a reduction in the production 
of IL-1β in all the stimulated cultures in which the drug has been added compared to no 
drug stimulated culture. 
12.  IMPACT OF THE STUDY FOR THE NATIONAL HEALTH SYSTEM 
Depression is one of the most prevalent diseases worldwide. Currently there are only 
symptomatic treatments with high resistance rate. With the discovery of new drug targets, 
it is possible to find a better treatment allowing a better management of the disease. This 
could improve the quality of life for patients, their families and society as a whole; while 
costs would be reduced as it will reduce recovery time, medical visits and absenteeism. 
Furthermore, as stated in several studies, chronic inflammation is the cause of multiple 
pathologies. Therefore, an effective treatment could help patients affected by other 
diseases to improve their quality of life. 
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13. ETHICAL QUESTIONS 
First of starting the study, it will be evaluated by the local ethic committees and will be 
carried out in accordance with the declaration of Helsinki. 
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16. GLOSSARY: 
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1. Sickness behaviour 
Sickness behaviour is a behavioural change that could have adaptive benefits8 for the sick 
animals/humans in terms of recovery and survivability because it conserves energy for 
fighting infection and healing wounds, while maintaining vigilance against attack 
(anxiety).2 
2. DAMPs 
DAMPs are components of dead/dying cells and damaged tissues able to trigger the 
Pattern Recognition Receptors. DAMP include: ATP, heat shock (HSP) and chromatin 
proteins, uric acid, high mobility group box 1 (HMGB1), amyloid, fragments of 
extracellular matrix components and molecules linked with oxidative stress (oxidized low 
density)11 
3. TLR: 
TLRs are the most widely studied PRRs are the TLR. These are membrane proteins that 
recognize and binds to proteins, lipids and nucleic acid molecules on infectious 
pathogens. The subsequent signalling, activates the innate immune system. 
4. Inflammasome: 
An Inflammasome is a large protein complex of certain Nod Like Receptors (NLR) with 
other proteins, including key proteases, that activates caspase-1 to generate IL-1 and IL-
18. Three NLRs (NLRP1, NLRP3 and NLRC4) have been shown to form 
Inflammasomes. The best characterized Inflammasome is the NLR3, which is expressed 
in monocytes, macrophages, neutrophils, dendritic cells and some lymphocytes and 
epithelial cells but also inside the brain in microglia and invasive macrophages. 11 
5. P2X7R: 
P2X7R is an ionotropic receptor located predominantly on microglia and macrophages 
which activates Inflammasome. This receptor is triggered in response to cellular danger 
signals, such as ATP. 12 
 
 
6. Glutathione: 
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Glutathione has important functions in the brain as an antioxidant, and it also acts as a 
neuromodulator of the glutamate ionotropic receptors, interacts with NMDA receptors, 
and protects against glutamate excitotoxicity. Glutathione depletion enhances the 
transcription and damaging effects of these cytokines and predisposes to a pro-
inflammatory environment compromising synaptic plasticity, memory, and learning. 
Lowered activity of the glutathione system is observed in neuro-immune disorders, 
including depression, ME/CFS, and Parkinson’s disease.14 
7. ATP 
ATP is a “warning molecule” for microglial activation and an endogenous agonist of 
P2X7R receptor of the Inflammasome. Moreover, extracellular ATP is used as a 
gliotransmitter for astrocytes, but it is also thought to be a neurotransmitter. 
8. CRP 
CRP (C-reactive protein) is an opsonin which recognizes phosphorylcoline and carbohydrates on 
bacteria, fungi and parasites, and is then bound by Fc receptors (FCRs) for IgG found on most 
phagocytes. That protein is released by the liver when it is stimulated by inflammatory cytokines. 
This has been utilized as a biomarker for detecting inflammation, in which levels exceeding 10 
mg/L are considered to predict inflammatory states.19 
 
 
 
 
 
 
 
 
 
 
 
9. Pro-inflammatory cytokines: 
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Cytokine Sources Target and effects 
IL-1β 
 Monocytes 
 Macrophages 
 Dendritic cells 
 NK cells 
 Non-immune cells 
(fibroblast, adipocytes, 
astrocytes and some 
smooth muscle cells) 
 
 Induction of local inflammation 
 Systemic effects (fever, acute 
phase response…) 
 Stimulation of neutrophil 
production 
TNF-α 
 
 Monocytes 
 Macrophages 
 T cells 
 NK cells 
 Neutrophils 
 Fibroblast 
 Regulates growth and 
differentiation of a wide variety of 
cell types. Cytotoxic 
 Promotes angiogenesis, bone 
resorption and thrombotic 
processes 
 Supresses lypogenic metabolism 
 Induction of acute phase proteins 
(liver) 
IL-6 
 
 Macrophages 
 Endothelial cells 
 Some T cells and B cells 
 Regulates B and T cell function 
 Induction of acute phase proteins 
(liver) 
 Effects on haematopoiesis 
 Influence adaptive immune system 
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17. APPENDIX 
17.1 RECENT CLINICAL TRIALS 
Recent clinical trials have shown that TNFα blockers are effective in decreasing 
depressive symptoms associated with inflammatory disorders.  
Workers Patients Treatment Results 
Tyring et al.31 
(2006) 
Psoriasis 
patients 
Etanercept 
Compared to placebo administration, 
Etanercept treatment led to an improvement of 
at least 50% in depression rating scales at week 
12. 
Bassukas et al.32 
(2008) 
Psoriasis 
patients 
Infliximab 
Stabilization or improvement of the 
manifestations of psychiatric morbidity 
Menter et al33 
(2010) 
Psoriasis 
patients 
Adalimumab 
Adalimumab treatment reduced symptoms of 
depression and improved health-related quality 
of life (GOL) in addition to improving psoriasis 
Lichtenstein et 
al. 34 
(2002) 
Crohn 
disease 
patients 
Infliximab 
Significantly improved GOL in patients with 
active CD, decreasing fatigue, depression and 
anger 
Persoons et al35 
(2005) 
Crohn 
disease 
patients 
Infliximab 
Reported the beneficial effects of infliximab on 
depression and psychological well-being in 
active CD 
Minderhoud et 
al36 
(2007) 
Crohn 
disease 
patients 
Infliximab 
Significantly reduced depression scores and 
improved the GOL as well as fatigue in a four-
week follow-up study 
Kekow. COMET 
study37 
(2010) 
Rheumatoid 
arthritis 
patients 
Etanercept 
Early treatment with ETN+MTX leads to 
significantly greater improvements in multiple 
dimensions of patient-reported outcomes 
(PROs) than MTX alone. 
Packham et al. 
ASCEND study38 
(2012) 
Ankylosing 
spondilitis 
Etanercept 
Improvement during routine clinical practice or 
following treatment with ETN.  Evaluation of 
Ankylosing Spondylitis Quality of Life (EASi-
QoL) domains have superior or comparable 
responsiveness than comparable measures. 
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17.2 INFORMED CONSENT 
 
HOJA DE INFORMACIÓN AL PACIENTE/DONANTE 
Estudio para conocer la diferencia entre el nivel de marcadores inflamatorios entre 
controles sanos y pacientes con Episodio Depresivo Mayor. Incluye la determinación de 
biomarcadores inflamatorios y el cultivo de células de los pacientes en sangre para 
analizar la eficacia de nuevos posibles fármacos contra la depresión. 
 Estimado paciente/control, 
El objetivo de este documento es resumirle de forma clara y concisa el propósito del 
estudio en el que le proponemos participar. Este documento puede contener palabras que 
no comprenda. Si es así, pídale al médico responsable del estudio o al personal que forma 
parte del mismo que le explique lo que no entienda. Cuando haya comprendido toda la 
información, y si desea participar en el estudio, se le pedirá que firme un consentimiento 
informado.  
El estudio que estamos realizando tiene como objetivo analizar la inflamación como una 
de las posibles causas de la depresión y estudiar posibles terapias para el tratamiento de 
la Depressión. Para ello necesitamos muestras de donantes sanos y pacientes con 
Depresion que nos permitan poder poner a punto este proyecto. 
Retirada del estudio 
Su participación en este estudio es totalmente voluntaria. Podrá retirar su consentimiento 
y abandonar el estudio en cualquier momento, sin tener que dar explicaciones a su médico 
y sin que por ello se comprometa su tratamiento y atención médica futura. 
Su médico también podrá retirarle del estudio en cualquier momento si considera que es 
lo mejor para usted, o no cumple con los criterios necesarios para participar. Podría ser 
retirado del estudio si se considera que su participación puede serle perjudicial, si precisa 
algún tipo de tratamiento no permitido en el estudio, si no sigue las instrucciones del 
estudio, si es mujer y se queda embarazada, o si se cancela el estudio.  
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Posibles riesgos e inconvenientes 
Los efectos adversos que puede presentar serán los mismos que pudiera con la extracción 
sanguínea y que no difiere del de cualquier extracción sanguínea de la práctica clínica 
habitual. 
Confidencialidad 
El acceso a sus datos clínico-asistenciales y biológicos se realizará guardando la más 
estricta confidencialidad de forma que no se viole la intimidad personal. Sus datos serán 
tratados de forma que la información que se obtenga no puede identificarle o asociarse a 
su persona. De esta forma usted no podrá ser identificado durante el análisis y la 
presentación de los resultados en publicaciones relacionadas con el estudio. Se le 
garantiza el estricto cumplimiento de la Ley de protección de datos personales (en España, 
la Ley 15/1999 De Diciembre de Protección de Datos Personales).  
Si usted acepta participar en el estudio, autoriza que además del médico y su equipo, su 
historia médica pueda ser revisada por el personal autorizado por el Promotor del estudio 
y por las Autoridades Sanitarias Reguladores. 
Compensación 
No está previsto el pago de los desplazamientos, ni pago por participar en el estudio. 
Resultados 
Una vez que el estudio haya concluido y se disponga de los resultados, su médico podrá 
informarle al respecto si lo desea. Si los resultados del estudio se publican y está 
interesado en conocerlos, se le proporcionará una copia de la publicación o se le facilitará 
el acceso a los resultados.  
Agradecimiento 
Le agradecemos el tiempo dedicado a leer este documento que debe guardar. Por favor, 
tómese el tiempo necesario antes de decidir si desea participar. Si decide tomar parte en 
el estudio, deberá firmar dos ejemplares de consentimiento informado y quedarse uno. El 
otro se quedará archivado en su historia clínica.  
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Si en cualquier momento durante el estudio le surgiera alguna duda al respecto, o bien 
caso de alguna urgencia, no dude en ponerse en contacto con: 
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HOJA DE CONSENTIMIENTO INFORMADO 
Estudio para conocer la diferencia entre el nivel de marcadores inflamatorios entre 
controles sanos y pacientes con Episodio Depresivo Mayor. Incluye la determinación de 
biomarcadores inflamatorios y cultivo de células de la sangre de los pacientes para 
analizar la eficacia de nuevos posibles fármacos contra la depresión. 
 He comprendido la información que se me ha proporcionado y he resuelto dudas que 
tenía al respecto con el profesional sanitario responsable.  
Autorizo al equipo médico que me trata a que me extraiga muestras de sangre y las envíe 
al Servicio de Inmunología del hospital Germans Trias i Pujol, para su procesamiento, 
almacenamiento y análisis. También doy mi consentimiento para la realización de los 
cuestionarios propios del estudio. 
Respecto a la utilización tanto de la información clínica de mi  historial médico como del 
material biológico sobrante una vez finalizado el estudio: 
Autorizo a que el material biológico sobrante (tratado de forma anónima), y los datos 
clínicos asociados se utilicen para investigación 
SÍ  NO  
Deseo que se me comunique información importante derivada de la investigación 
SI  NO  
Autorizo a ser contactado en el caso de necesitar más información o muestras biológicas 
SI  NO  
 
 
 
 
 
Nombre y apellidos de la persona que 
obtiene el consentimiento 
  
 
Firma 
 
 
 
 
 
Lugar y fecha 
Nombre y apellidos del paciente o  
representante legal  
 
 
Firma 
 
 
 
 
 
Lugar y fecha 
